Inverness carries on along acquisition trail
This article was originally published in Clinica
Inverness Medical Innovations has entered an acquisition agreement with protein-based diagnostics specialist Matritech that will see it clinch its sixth purchase of the year. The Matritech buy, expected to close in the fourth quarter of 2007, will cost Inverness $36m in common stock, possibly highlighting that such prolific purchases have taken their toll on the company's financial reserves.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.